NCT00697125已完成2 期
Study to Evaluate the Immunogenicity and Reactogenicity of Various Formulations of GSK Biologicals' (Previously SmithKline Beecham Biologicals') Recombinant Hepatitis B Vaccine With Different Adjuvants in Healthy Adult Volunteers
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Occurrence and intensity of solicited local and general symptoms
研究概览
简要总结
The purpose of this study is to evaluate the immunogenicity and reactogenicity of various formulations of recombinant hepatitis B vaccine with different adjuvants in healthy adult volunteers following the 0, 1, 6 months schedule
详细描述
At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Between 18 and 40 years old.
- •Written informed consent will have been obtained from the subjects.
- •Good physical condition as established by physical examination and history taking at the time of entry.
- •Female participants will avoid becoming pregnant during the study period and they will have been on a contraceptive program for at least 2 months before entry
排除标准
- •Pregnancy or lactation.
- •Serological signs of HBV infection
- •Elevated serum liver enzymes
- •Any vaccination against hepatitis B in the past.
- •Any previous administration of MPL.
- •History of significant and persisting hematologic, hepatic, renal, cardiac or respiratory disease.
- •Axillary temperature > 37.5°C at the time of injection.
- •Any acute disease at the moment of entry.
- •Chronic alcohol consumption.
- •Any treatment with immunosuppressive or immunostimulant therapy.
- •Any chronic drug treatment, which in the investigator's opinion, precludes inclusion into the study.
- •History of allergic disease likely to be stimulated by any component of the vaccine.
- •Administration of any other vaccine(s) or any immunoglobulin during the study period.
- •Simultaneous participation in any other clinical trial.
研究组 & 干预措施
Group A
Active Comparator
干预措施: Engerix™-B (Biological)
Group B
Experimental
干预措施: Hepatitis B vaccine, experimental formulation (Biological)
Group C
Experimental
干预措施: HBV-MPL vaccine (208129) (Biological)
结局指标
主要结局
Occurrence and intensity of solicited local and general symptoms
时间窗: 8 days follow-up after vaccination
次要结局
- Anti-HBs antibody concentrations(Months 0, 1, 3, 6, 7, 8 and 12)
- Occurrence, intensity of unsolicited adverse events(30-day follow-up after vaccination)
- Occurrence of serious adverse events(During the study period up to 30 days after last vaccination)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 YearsInfluenza, HumanNCT03275389GlaxoSmithKline470
已完成
3 期
Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-BHepatitis BNCT00698087GlaxoSmithKline60
已完成
2 期
Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell LymphomaInfluenzaNCT00307177National Institute of Allergy and Infectious Diseases (NIAID)28
已完成
3 期
Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-RespondersHepatitis BNCT00697931GlaxoSmithKline116
已完成
1 期
Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory AdultsInfluenzaNCT00133471National Institute of Allergy and Infectious Diseases (NIAID)96